Objective: To probe into the clinical efficacy and safety of different doses of ivabradine in the treatment of viral myocarditis (VMC) in children. Methods: Eighty-four children with VMC admitted to our hospital from Dec. 2017 to Nov. 2018 were selected to be divided into the control group and the observation group via the admission sequence

with 42 cases in each group. The control group was given ivabradine hydrochloride 2.5 mg

and the observation group received ivabradine hydrochloride 5 mg

twice a day for 2 weeks. The clinical efficacy of two groups was compared. The serum cardiac troponin I (cTnI)

cardiac troponin T (cTnT)

B-type natriuretic peptide precursor (NT-proBNP) levels

and heart rate (HR) were observed before and after treatment. The adverse drug reactions were recorded. Results: The total effective rate of the observation group (90.48%) was higher than that of the control group (76.19%)

with statistically significant difference (P<0.05). After treatment

the levels of cTnI

cTnT

NT-proBNP and HR in the observation group were significantly lower than those in the control group (P<0.05). Adverse drug reactions in two groups were relatively mild

no drug withdrawal was required

and the difference was not statistically significant (P>0.05). Conclusion: The clinical efficacy of ivabradine in the treatment of VMC in children is significant. Higher dose of ivaredine can achieve better therapeutic effects

which is safe and feasible

and has higher clinical application value